Navigation Links
Senetek PLC Investor Hotline Goes Live
Date:5/15/2009

Call 877-SENETEK or 707-259-6278

NAPA, Calif., May 15 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, announced that an up-to-date audio recording of Company news and developments is now available by calling 877-SENETEK in the United States and Canada and 707-259-6278 from international locations.

"We are pleased to provide this service to our investors as a supplement to news releases, shareholder teleconferences and our quarterly and annual filings. Our mission is to keep the Senetek shareholder updated in a timely fashion," stated Frank J. Massino, Chairman and Chief Executive Officer of Senetek.

About Senetek PLC:

Senetek PLC (OTCBB: SNKTY) is a life sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of kinetin, the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's websites:

www.senetekplc.com

www.pyratine6.com

www.pyratinexr.com

or call: 877-SENETEK (United States and Canada) 707-259-6278 (International Locations)

This news release contains statements that may be considered 'forward-looking s
'/>"/>

SOURCE Senetek PLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Senetek PLC Announces New Investor Communication Hotline
2. Senetek PLC Announces 2008 Annual General Meeting Voting Results
3. Senetek PLC Acquires Rights to Additional Anticancer RNAi Technology
4. Senetek Affirms Strong Financial Position
5. Senetek PLC Reports Second Quarter 2008 Financial Results
6. Senetek PLC Reports First Quarter 2008 Financial Results
7. Senetek PLC Announces Appointments of Key Personnel
8. Senetek PLC in Dispute With Marketer of Pyratine-6(TM)
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
11. China-Biotics, Inc. to Present at CCG Investor Relations China Rising Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Local veterinarian, Dr. Keith ... are seeking candidates to participate in an investigational study ... The ultimate goal of this study is to determine ... one or two arthritically affected joints can help reduce ... Candidates for the current investigational study must be older ...
(Date:8/29/2014)... August 29, 2014 Intrinsic Imaging, ... certified, GAMP® 5 compliant imaging core lab, announced ... Phase II clinical trial to assess a new ... this trial, Intrinsic Imaging will provide comprehensive imaging ... protocol and charter development, site qualification, site training ...
(Date:8/28/2014)... MA (PRWEB) August 28, 2014 “This kit ... test to screen from 0 to 150 ppb,” said Mark ... is a significant benefit to plant owners and USDA-GIPSA inspection ... and other commodities. Testing can take place in a matter ... only can the plant test the feed and grain before ...
(Date:8/28/2014)... August 28, 2014 The ability for ... culture that will allow individuals to perform at the ... important for employers looking to compete in this post–recession ... embracing this trend, as the sector increasingly focuses on ... company, which will have real results on the organization's ...
Breaking Biology Technology:Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3
... For a biotech company, raising money is a saga that never ... do two things: execute on the timely achievement of key milestones ... of your next financing and where and who the money will ... in for a single round whereas most VCs usually commit for ...
...
... predicts the Alzheimer's disease drug market in ... by 15 percent annually for the next five ... entitled "Global Markets for Alzheimer's Disease Medications 2005," ... in an Alzheimer's drug market that generated more ...
Cached Biology Technology:Financing of biotech companies so far in 2005: A Midwest odyssey 2Financing of biotech companies so far in 2005: A Midwest odyssey 3Financing of biotech companies so far in 2005: A Midwest odyssey 4Financing of biotech companies so far in 2005: A Midwest odyssey 5Alzheimer's drug market to hit $5.5 billion by 2009, study says 2
(Date:8/31/2014)... One of the greatest challenges in modern medicine is ... but with minimal toxicity and side-effects to the patient. ... of the drug molecule. Ideally, the drug should have ... target, so that it binds it with high specificity. ... developed a synthetic amino acid that can impact the ...
(Date:8/31/2014)... Climate Change , suggests that if current trends continue ... global targets for total greenhouse gas (GHG) emissions in 2050. ... carefully about the food we choose and its environmental impact. ... one of a number of actions that need to be ... enough food for all. , As populations rise and ...
(Date:8/29/2014)... Researchers at UC Davis have made some surprising ... infection. Studying simian immunodeficiency virus (SIV), the team ... Paneth cells are early responders to viral invasion ... producing a cytokine called interleukin-1 beta (IL-1β). ... IL-1β causes breakdown of the gut epithelium that ...
Breaking Biology News(10 mins):A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3Changing global diets is vital to reducing climate change 2Changing global diets is vital to reducing climate change 3Changing global diets is vital to reducing climate change 4The early cost of HIV 2
... at Boulder team working at 16,400 feet in the ... retreating glacier ice can swiftly establish a thriving community ... alpine plants. The discovery is the first to ... one of the most extreme environments on Earth and ...
... choice all too frequently has come down to living ... indoor allergens. Today, The Clorox Company extends its ... Anti-Allergen Fabric Spray, a new product to help manage ... Clorox® Anywhere® Anti-Allergen Fabric Spray denatures dust mite ...
... Humans aren,t the only ones who like fatty foods - ... the Bearded Vulture Study and Protection Group in El Pont ... discard less energy-dense bones and choose only the bones containing ... to its young. His findings will be published this week ...
Cached Biology News:As Andean glacier retreats, tiny life forms swiftly move in, CU-Boulder study shows 2As Andean glacier retreats, tiny life forms swiftly move in, CU-Boulder study shows 3The Clorox Company's new indoor allergen product reduces common indoor allergens up to 90 percent 2Scavenger birds chew the fat 2
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to amino acids 196-244 of E. coli YebU....
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
... Antibody to CRF The ... ovine CRF sequence that it ... fibres are found in the ... brain in colchicine treated 4% ...
... siSolutions siRNA Custom Synthesis ... effective duplex RNA to knockdown ... 21-mers (19 RNA base pairs ... recently-published 27-mers, or other lengths ...
Biology Products: